SPC
GTBP icon

Sigma Planning Corp’s GT Biopharma GTBP Stock Holding History

Sigma Planning Corp’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-680
Closed -$4.92K – 985
2023
Q3 		$4.92K Hold
680
– – ﹤0.01% 1191
2023
Q2 		$6.36K Sell
680
-83
-11% -$861 ﹤0.01% 1194
2023
Q1 		$12.6K Buy
763
+50
+7% +$1.15K ﹤0.01% 1286
2022
Q4 		$18.9K Hold
713
– – ﹤0.01% 1242
2022
Q3 		$38K Hold
713
– – ﹤0.01% 1230
2022
Q2 		$64K Hold
713
– – ﹤0.01% 1236
2022
Q1 		$62K Buy
+713
New +$62.9K ﹤0.01% 1330

Other funds holding GTBP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sigma Planning Corp's GTBP Position: Q4 2023 in Review

Sigma Planning Corp sold out of GT Biopharma (GTBP) in Q4 2023, closing a stake of 680 shares — an estimated $4.92K sold.

Sigma Planning Corp first reported a position in GTBP in Q1 2022 and held it in 7 quarters. The position peaked at $64K in Q2 2022. 33 funds tracked by Wall St. Rank hold GTBP as of Q4 2023.

  • Sigma Planning Corp reported no remaining GT Biopharma position as of Q4 2023 after selling out during the quarter.
  • Sigma Planning Corp sold 680 GT Biopharma shares in Q4 2023, an estimated $4.92K.
  • Sigma Planning Corp first reported a position in GT Biopharma in Q1 2022 and held it in 7 quarters.
  • Sigma Planning Corp's GT Biopharma position peaked at $64K in Q2 2022.
  • 33 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2023.

Based on Sigma Planning Corp's 13F filing for Q4 2023, filed 1 Feb 2024.